论文部分内容阅读
目的探讨人表皮生长因子受体(EGFR)家族中的HER-3和HER-4在胃癌中的表达及临床意义。方法采用免疫组织化学SP法检测161例患者胃癌组织中HER-3和HER-4的表达。结果胃癌组织中HER-3阳性率为55.9%(90/161),高于正常胃组织的5.0%(1/20)(P<0.05);胃癌组织中HER-4阳性率为68.3%(110/161),正常胃组织为0(0/20)(P<0.01)。HER-3在胃癌组织中的表达程度与胃癌的侵犯深度、TNM分期、淋巴结转移、神经脉管的侵犯及预后有关(P<0.05,P<0.01);HER-4在胃癌中的表达与侵犯深度、TNM分期及远处转移相关(P<0.05)。结论 HER-3和HER-4的表达与胃癌的发生、发展有关;HER-3有可能成为胃癌靶向治疗中改善胃癌患者预后的重要靶点。
Objective To investigate the expression and clinical significance of HER-3 and HER-4 in human epidermal growth factor receptor (EGFR) family. Methods Immunohistochemical SP method was used to detect the expression of HER-3 and HER-4 in gastric cancer tissues of 161 patients. Results The positive rate of HER-3 in gastric cancer was 55.9% (90/161), which was higher than 5.0% (1/20) in normal gastric tissue (P<0.05). The positive rate of HER-4 in gastric cancer was 68.3% (110%). /161), normal gastric tissue was 0 (0/20) (P < 0.01). The expression of HER-3 in gastric cancer was related to the invasion depth of gastric cancer, TNM stage, lymph node metastasis, neurovascular invasion and prognosis (P<0.05, P<0.01); HER-4 expression and invasion in gastric cancer Depth, TNM staging and distant metastasis were related (P<0.05). Conclusion The expression of HER-3 and HER-4 is related to the occurrence and development of gastric cancer. HER-3 may be an important target for improving the prognosis of gastric cancer in targeted therapy of gastric cancer.